TILT Holdings Inkomsten in het verleden
Verleden criteriumcontroles 0/6
TILT Holdings has been growing earnings at an average annual rate of 42.2%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 5.6% per year.
Belangrijke informatie
42.2%
Groei van de winst
49.2%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 6.0% |
| Inkomstengroei | 5.6% |
| Rendement op eigen vermogen | -450.5% |
| Nettomarge | -52.1% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe TILT Holdings geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 146 | -76 | 34 | 0 |
| 31 Mar 24 | 161 | -67 | 34 | 0 |
| 31 Dec 23 | 166 | -62 | 38 | 0 |
| 30 Sep 23 | 173 | -114 | 42 | 0 |
| 30 Jun 23 | 169 | -121 | 44 | 0 |
| 31 Mar 23 | 174 | -101 | 49 | 0 |
| 31 Dec 22 | 174 | -107 | 49 | 0 |
| 30 Sep 22 | 184 | -54 | 47 | 0 |
| 30 Jun 22 | 197 | -38 | 47 | 0 |
| 31 Mar 22 | 198 | -30 | 44 | 0 |
| 31 Dec 21 | 203 | -35 | 42 | 0 |
| 30 Sep 21 | 191 | -60 | 43 | 0 |
| 30 Jun 21 | 177 | -63 | 40 | 0 |
| 31 Mar 21 | 165 | -73 | 40 | 0 |
| 31 Dec 20 | 158 | -52 | 40 | 0 |
| 30 Sep 20 | 144 | -28 | 33 | 0 |
| 30 Jun 20 | 151 | 0 | 0 | 0 |
| 31 Mar 20 | 153 | -40 | 55 | 0 |
| 31 Dec 19 | 147 | -122 | 122 | 0 |
| 30 Sep 19 | 122 | -638 | 153 | 0 |
| 30 Jun 19 | 77 | -671 | 185 | 0 |
| 31 Mar 19 | 38 | -626 | 126 | 0 |
| 31 Dec 18 | 4 | -550 | 52 | 0 |
Kwaliteitswinsten: TLLT.F is currently unprofitable.
Groeiende winstmarge: TLLT.F is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: TLLT.F is unprofitable, but has reduced losses over the past 5 years at a rate of 42.2% per year.
Versnelling van de groei: Unable to compare TLLT.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: TLLT.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendement op eigen vermogen
Hoge ROE: TLLT.F has a negative Return on Equity (-450.51%), as it is currently unprofitable.